Addex Therapeutics and Perceptive Advisors establish Neurosterix with $63M investment for developing allosteric modulators for neurological disorders.
Addex Therapeutics and Perceptive Advisors launch Neurosterix with $63M investment. Neurosterix focuses on developing allosteric modulators to treat underserved neurological disorders, backed by a preclinical assets portfolio and allosteric modulator drug discovery technology platform. Perceptive Xontogeny Venture Fund II leads the funding, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.
April 03, 2024
5 Articles